Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models
- 4 December 2003
- journal article
- Published by Wiley in The Prostate
- Vol. 59 (1) , 22-32
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Loss of heterozygosity of nucleotide excision repair factors in sporadic ovarian, colon and lung carcinomas: implication for their roles of carcinogenesis in human solid tumorsCancer Letters, 2001
- Hormone-refractory prostate cancer: a multi-step and multi-event processProstate Cancer and Prostatic Diseases, 2001
- Treatment Options in Hormone-Refractory Prostate CancerDrugs, 2001
- Quantitative Determination of the Expression of Xeroderma Pigmentosum F Gene in Human Nonmelanoma Skin CancersBiochemical and Biophysical Research Communications, 2000
- Systematic variation in gene expression patterns in human cancer cell linesNature Genetics, 2000
- Arrest of Replication Fork Progression at Sites of Topoisomerase II-Mediated DNA Cleavage in Human Leukemia CEM Cells Incubated with VM-26Biochemistry, 1997
- p53 oncogene mutations in three human prostate cancer cell linesThe Prostate, 1993
- Immunohistochemistry and biochemistry in detection of androgen, progesterone, and estrogen receptors in benign and malignant human prostatic tissueThe Prostate, 1992
- Inhibition of DNA synthesis and cytotoxic effects of some DNA topoisomerase II and gyrase inhibitors in Chinese hamster V79 cellsMutation Research Letters, 1990
- Molecular and biochemical pharmacology of mitoxantroneCancer Treatment Reviews, 1983